{"content":"<li class=\"n-box-item date-title\" data-end=\"1459828799\" data-start=\"1459742400\" data-txt=\"Sunday, December 22, 2019\">Monday, April  4, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3171388\" data-ts=\"1459807024\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/D\" target=\"_blank\">D</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171388-dominion-to-sell-10_2m-common-shares-for-750m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dominion to sell 10.2M common shares for ~$750M</a></h4><ul>     <li>Dominion Resources (NYSE:<a href=\"https://seekingalpha.com/symbol/D\" title=\"Dominion Energy, Inc.\">D</a>) <font color=\"red\">-1.5%</font> AH after saying it plans to sell 10.2M common shares, raising ~$750M of gross proceeds, through an underwritten public offering to Citigroup.</li>\n<li>D says it plans to use the proceeds for general corporate purposes, including to help fund its planned <a href=\"https://seekingalpha.com/news/3068996-dominion-resources-buy-questar-4_4b-deal\" target=\"_blank\">$4.4B acquisition</a> of Questar (NYSE:<a href=\"https://seekingalpha.com/symbol/STR\" title=\"Questar Corporation\">STR</a>) and to repay short-term debt.</li>\n<li>Now read <a href=\"https://seekingalpha.com/news/3169348-purchase-agreements-place-atlantic-coast-pipeline-dominion-says\" target=\"_blank\"><strong>Purchase agreements in place for Atlantic Coast pipeline, Dominion says</strong></a>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171388\" data-linked=\"Dominion to sell 10.2M common shares for ~$750M\" data-tweet=\"$D $D $STR - Dominion to sell 10.2M common shares for ~$750M https://seekingalpha.com/news/3171388-dominion-to-sell-10_2m-common-shares-for-750m?source=tweet\" data-url=\"https://seekingalpha.com/news/3171388-dominion-to-sell-10_2m-common-shares-for-750m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171386\" data-ts=\"1459806127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171386-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/BTU' title='Peabody Energy Corp.'>BTU</a> <font color='green'>+4.4%</font>. <a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a> <font color='green'>+4.2%</font>. <a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='green'>+3.5%</font>. <a href='https://seekingalpha.com/symbol/NEU' title='NewMarket Corporation'>NEU</a> <font color='green'>+2.6%</font>. <a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles NV'>FCAU</a> <font color='green'>+2.6%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/KBH' title='KB Home'>KBH</a> <font color='red'>-22.2%</font>. <a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='red'>-19.7%</font>. <a href='https://seekingalpha.com/symbol/NATI' title='National Instruments Corporation'>NATI</a> <font color='red'>-11.4%</font>. <a href='https://seekingalpha.com/symbol/JD' title='JD.com'>JD</a> <font color='red'>-7.1%</font>. <a href='https://seekingalpha.com/symbol/KEYS' title='Keysight Technologies Inc.'>KEYS</a> <font color='red'>-4.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171386\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$BTU $RH $SBGL - After Hours Gainers / Losers https://seekingalpha.com/news/3171386-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3171386-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171379\" data-ts=\"1459804160\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171379-investors-doubt-efficacy-of-clovis-lung-cancer-med-rociletinib-shares-off-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors doubt efficacy of Clovis lung cancer med rociletinib, shares off 11%</a></h4><ul>\n<li>Clovis Oncology (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CLVS\" title=\"Clovis Oncology\">CLVS</a>) had a rough day today as shares fell <font color=\"red\">11%</font> on more than double normal volume. There appears to be a growing lack of confidence that the company's Breakthrough Therapy-tagged lung cancer candidate, rociletinib, will get a \"thumbs up\" at next week's Ad Comm meeting (Tuesday, April 12). The noise continues to build that the company has been less than forthright with the data from the Phase 3 study so there will be substantial scrutiny on the briefing docs that will be released no later (hopefully) than Friday, April 8.</li>\n<li>Shares plummeted last November when the company announced that the FDA requested additional efficacy data on both the 500 mg and 625 mg dosage groups. It also disclosed that the confirmed response rates were about 20 percentage points lower than expected (28% for 500 mg and 34% for 625 mg). So low, in fact, that its effectiveness appears to be well below rival AstraZeneca's (NYSE:<a href=\"https://seekingalpha.com/symbol/AZN\" title=\"AstraZeneca Group plc\">AZN</a>) <a href=\"https://www.tagrisso.com/home.html\" target=\"_blank\">Tagrisso </a>(osimertinib), which showed an overall response rate of 59% in clinical studies. One industry expert, Kapil Dhingra, <a href=\"http://www.fiercebiotech.com/story/did-clovis-play-deceptive-game-rociletinib-data-leadup-phiii-stunner/2016-04-03\" target=\"_blank\">believes </a>the company knew the confirmed response rates at the time of the ASCO presentations, two months before its NDA filing was completed, but failed to disclose the information to the market.</li>\n<li>The FDA's action date (PDUFA) is June 28. It was originally March 30 before the agency requested the additional data.</li>\n<li>Shares have lost ~85% of their value since mid-September.</li>\n<li>Now read <a href=\"https://seekingalpha.com/article/3961314-clovis-oncology-trying-rebuild-bright-outlook\" target=\"_blank\">Clovis Oncology Trying To Rebuild A Once-Bright Outlook</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171379\" data-linked=\"Investors doubt efficacy of Clovis lung cancer med rociletinib, shares off 11%\" data-tweet=\"$CLVS $CLVS $AZN - Investors doubt efficacy of Clovis lung cancer med rociletinib, shares off 11% https://seekingalpha.com/news/3171379-investors-doubt-efficacy-of-clovis-lung-cancer-med-rociletinib-shares-off-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3171379-investors-doubt-efficacy-of-clovis-lung-cancer-med-rociletinib-shares-off-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171362\" data-ts=\"1459801744\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171362-tesla-motors-misses-q1-delivery-forecast\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla Motors misses Q1 delivery forecast</a></h4><ul> <li>Tesla Motors (NASDAQ:<a href=\"https://seekingalpha.com/symbol/TSLA\" title=\"Tesla, Inc.\">TSLA</a>) announces it delivered 14,820 vehicles in Q1 to miss the forecast of 16K. A shortage of key parts for the tech-heavy Model X played a factor in the output number.</li>\n<li>The build rate for the last full week in March moved up to 750 Model X vehicles.</li> <li>Despite the light quarter, the company still expects to delivery 80K to 90K during the year.</li> <li>TSLA <font color=\"red\">-2.4%</font> in a volatile after-hours session.</li>\n<li>Now read <a href=\"https://seekingalpha.com/article/3963051-b-tesla-b-model-3-reservations-disrupt-auto-battery-markets\" target=\"_blank\"><strong>Tesla Model 3 Reservations To Disrupt Auto, Battery Markets</strong></a><strong> </strong>\n</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3171362\" data-linked=\"Tesla Motors misses Q1 delivery forecast\" data-tweet=\"$TSLA - Tesla Motors misses Q1 delivery forecast https://seekingalpha.com/news/3171362-tesla-motors-misses-q1-delivery-forecast?source=tweet\" data-url=\"https://seekingalpha.com/news/3171362-tesla-motors-misses-q1-delivery-forecast\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>344&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171377\" data-ts=\"1459799856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWN\" target=\"_blank\">SWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171377-southwestern-energy-takes-advantage-of-accounting-trick-jumps-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southwestern Energy takes advantage of accounting trick, jumps 9%</a></h4><ul>     <li>Southwestern Energy (<a href=\"https://seekingalpha.com/symbol/SWN\" title=\"Southwestern Energy Co.\">SWN</a> <font color=\"green\">+8.8%</font>) rebounds after disclosing it <a href=\"http://www.sec.gov/Archives/edgar/data/7332/000000733216000046/swn040416form8k.htm\" target=\"_blank\">repaid a $1.55B loan</a> borrowed on March 30 through its bank credit facility just two days later on April 1.</li>     <li>SWN says that maxing out the short-term loan and applying the funds as an asset on its consolidated balance sheet on the final day of Q1 worked to expand the company's flexibility by ~$232M by increasing the maximum amount of secured debt or subsidiaries debt it can take on during Q2.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171377\" data-linked=\"Southwestern Energy takes advantage of accounting trick, jumps 9%\" data-tweet=\"$SWN - Southwestern Energy takes advantage of accounting trick, jumps 9% https://seekingalpha.com/news/3171377-southwestern-energy-takes-advantage-of-accounting-trick-jumps-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3171377-southwestern-energy-takes-advantage-of-accounting-trick-jumps-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171345\" data-ts=\"1459799346\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTR\" target=\"_blank\">NTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171345-potash-downgraded-cibc-which-sees-lower-2016-eps-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Potash downgraded at CIBC, which sees lower 2016 EPS guidance</a></h4><ul>     <li>Potash (POT <font color=\"red\">-3.9%</font>) and Mosaic (<a href=\"https://seekingalpha.com/symbol/MOS\" title=\"The Mosaic Company\">MOS</a> <font color=\"red\">-4.1%</font>) are <a href=\"http://business.financialpost.com/investing/trading-desk/potash-corp-may-reduce-2016-guidance-cibc\" target=\"_blank\">downgraded</a> to Sector Perform from Sector Outperform at CIBC, which says potash markets could remain soft for the foreseeable future due to price competition among the producers.</li>\n<li>Potash prices have continued to decline in recent weeks, meaning POT's 2016 earnings guidance announced barely two months ago already looks shaky, the firm says, adding that it believes the company will reduce the low end of its $0.90-$1.20 EPS outlook.</li>\n<li>CIBC also is concerned about POT's dividend, even though it already has been lowered this year; the firm calculates the payout ratio at 131% in 2016 and 78% in 2017.</li>\n<li>Now read <a href=\"https://seekingalpha.com/article/3961251-potash-can-fertilize-future-profits-portfolio\" target=\"_blank\"><strong>How Potash can fertilize future profits in your portfolio</strong></a>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171345\" data-linked=\"Potash downgraded at CIBC, which sees lower 2016 EPS guidance\" data-tweet=\"$NTR $NTR $MOS - Potash downgraded at CIBC, which sees lower 2016 EPS guidance https://seekingalpha.com/news/3171345-potash-downgraded-cibc-which-sees-lower-2016-eps-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3171345-potash-downgraded-cibc-which-sees-lower-2016-eps-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171342\" data-ts=\"1459798776\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBI\" target=\"_blank\">MBI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171342-bond-insurers-lower-after-hedge-fund-suit-against-puerto-rico\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bond insurers lower after hedge fund suit against Puerto Rico</a></h4><ul>\n<li>A group of hedge funds sued Puerto Rico's Government Development Bank aiming to halt the GDB from making transfer payments to selected creditors until after the bank's debt has been restructured.</li>\n<li>MBIA (<a href=\"https://seekingalpha.com/symbol/MBI\" title=\"MBIA Inc.\">MBI</a> <font color=\"red\">-5.9%</font>), Assured Guaranty (<a href=\"https://seekingalpha.com/symbol/AGO\" title=\"Assured Guaranty Ltd.\">AGO</a> <font color=\"red\">-2.7%</font>), and Ambac (<a href=\"https://seekingalpha.com/symbol/AMBC\" title=\"Ambac Financial\">AMBC</a> <font color=\"red\">-3.9%</font>) are all lower, but the suit isn't a negative for the insurers, <a href=\"http://researchwiseny.btig.com/ResearchLibraryAnalec/DownloadResearch.aspx?E=chihk-b\" target=\"_blank\">says BTIG's Mark Palmer</a>, noting media reports are describing it as applying to all of Puerto Rico's debt.</li>\n<li>He notes one reporter's tweet: \u201cA group of hedge funds sues to keep Puerto Rico from making payments to creditors prior to restructuring its debt.\"</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171342\" data-linked=\"Bond insurers lower after hedge fund suit against Puerto Rico\" data-tweet=\"$MBI $MBI $AGO - Bond insurers lower after hedge fund suit against Puerto Rico https://seekingalpha.com/news/3171342-bond-insurers-lower-after-hedge-fund-suit-against-puerto-rico?source=tweet\" data-url=\"https://seekingalpha.com/news/3171342-bond-insurers-lower-after-hedge-fund-suit-against-puerto-rico\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171341\" data-ts=\"1459798638\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171341-petrobrasminus-10-on-report-lower-gasoline-diesel-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras -10% on report it could lower gasoline, diesel prices</a></h4><ul>     <li>Petrobras (<a href=\"https://seekingalpha.com/symbol/PBR\" title=\"Petrobras - Petroleo Brasileiro S.A.\">PBR</a> <font color=\"red\">-10.4%</font>) plunges following a weekend report that it <a href=\"http://www.reuters.com/article/us-petrobras-gasoline-idUSKCN0X00S4\" target=\"_blank\">could cut gasoline and diesel prices</a> as soon as today, reversing hikes last year meant to help make up for years of artificially low prices.</li>     <li>A decrease, reported by the <em>O Globo</em> newspaper without citing any sources and without specifying how much PBR could raise pirces, would  seek to make pump prices reflect the drop in global oil prices and lower demand for fuel in Brazil, which is suffering a sharp recession.</li>     <li>\"With the entire investment community avidly monitoring  Brazil's political agenda, the timing of such a decision could be <a href=\"https://finance.yahoo.com/news/emerging-markets-brazil-shares-currency-162804654.html\" target=\"_blank\">heavily  misinterpreted</a>, negating some of the hard work done in regaining  investor confidence,\" say analysts at BTG Pactual.</li>     <li>\n<a href=\"http://www.reuters.com/article/us-brazil-petrobras-idUSKCN0X120X\" target=\"_blank\">No word yet from the company</a>, as Reuters reports two company officials denied a decision was imminent but that such measures are always under analysis.</li>\n<li>Now read <a href=\"https://seekingalpha.com/news/3170911-petrobras-eyes-12k-job-cuts-voluntary-layoffs\" target=\"_blank\"><strong>Petrobras eyes up to 12K job cuts through voluntary layoffs</strong></a>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171341\" data-linked=\"Petrobras -10% on report it could lower gasoline, diesel prices\" data-tweet=\"$PBR - Petrobras -10% on report it could lower gasoline, diesel prices https://seekingalpha.com/news/3171341-petrobrasminus-10-on-report-lower-gasoline-diesel-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3171341-petrobrasminus-10-on-report-lower-gasoline-diesel-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171336\" data-ts=\"1459797728\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STXS\" target=\"_blank\">STXS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171336-early-adopter-of-stereotaxis-niobe-system-passes-1000-procedure-mark-shares-up-50\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Early adopter of Stereotaxis Niobe system passes 1,000-procedure mark; shares up 50%</a></h4><ul>\n<li>Thinly traded nano cap Stereotaxis (<a href=\"https://seekingalpha.com/symbol/STXS\" title=\"Stereotaxis, Inc.\">STXS</a> <font color=\"green\">+49.5%</font>) announces that an early adopter of its Niobe remote magnetic navigation system, Hartford, CT-based Hoffman Heart and Vascular Institute at Saint Francis Hospital and Medical Center, recently completed its 1,000th cardiac ablation procedure. The facility is the company's top user of its technology in New England.</li>\n<li>Niobe enables the physician to better visualize and control an ablation catheter.</li>\n<li>Shares are up on a 40x surge in volume.</li>\n<li>Now read <a href=\"https://seekingalpha.com/article/1974241-stereotaxis-interview-of-experienced-doctor-with-stereotaxis-robotic-system\" target=\"_blank\">Stereotaxis - Interview of Experienced Doctor With Stereotaxis' Robotic System </a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171336\" data-linked=\"Early adopter of Stereotaxis Niobe system passes 1,000-procedure mark; shares up 50%\" data-tweet=\"$STXS - Early adopter of Stereotaxis Niobe system passes 1,000-procedure mark; shares up 50% https://seekingalpha.com/news/3171336-early-adopter-of-stereotaxis-niobe-system-passes-1000-procedure-mark-shares-up-50?source=tweet\" data-url=\"https://seekingalpha.com/news/3171336-early-adopter-of-stereotaxis-niobe-system-passes-1000-procedure-mark-shares-up-50\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171335\" data-ts=\"1459797457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MMP\" target=\"_blank\">MMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171335-magellan-midstream-downgraded-wunderlich-which-sees-little-upside-left\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Magellan Midstream downgraded at Wunderlich, which sees little upside left</a></h4><ul>     <li>Magellan Midstream Partners (<a href=\"https://seekingalpha.com/symbol/MMP\" title=\"Magellan Midstream Partners, L.P.\">MMP</a> <font color=\"red\">-2.9%</font>) is <a href=\"http://blogs.barrons.com/incomeinvesting/2016/04/04/magellan-midstream-upside-called-into-question/?mod=BOL_hp_blog_ii\" target=\"_blank\">downgraded to Hold</a> from Buy with a $68 price target at Wunderlich, which says that, despite its ability to grow profits and distributions to shareholders, it does not see much room for upside in the shares.</li>     <li>The firm says it is  encouraged by MMP's outlook to generate more EBITDA from existing assets, but while the company needs only $300M-$500M annual capex to  achieve 8%-10% distribution growth and growth opportunities remain, the figures already were mostly factored into its expectations</li>     <li>Separately, MMP and TransMontaigne Partners (<a href=\"https://seekingalpha.com/symbol/TLP\" title=\"TransMontaigne Partners, L.P.\">TLP</a> <font color=\"green\">+0.7%</font>) say they are jointly assessing a 150-mile diameter pipeline capable of moving 150K bbl/day of refined products.</li>\n<li>Now read <a href=\"https://seekingalpha.com/news/3168229-credit-suisse-downgrades-12-mlps-rally-plays\" target=\"_blank\"><strong>Credit Suisse downgrades 12 MLPs as rally plays out</strong></a>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171335\" data-linked=\"Magellan Midstream downgraded at Wunderlich, which sees little upside left\" data-tweet=\"$MMP $MMP $TLP - Magellan Midstream downgraded at Wunderlich, which sees little upside left https://seekingalpha.com/news/3171335-magellan-midstream-downgraded-wunderlich-which-sees-little-upside-left?source=tweet\" data-url=\"https://seekingalpha.com/news/3171335-magellan-midstream-downgraded-wunderlich-which-sees-little-upside-left\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171319\" data-ts=\"1459796838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYTR\" target=\"_blank\">CYTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171319-cytrx-hits-target-number-of-progression-events-in-late-stage-aldoxorubicin-study-in-soft\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytRx hits target number of progression events in late-stage aldoxorubicin study in soft tissue cancer; shares up 14%</a></h4><ul>\n<li>CytRx (<a href=\"https://seekingalpha.com/symbol/CYTR\" title=\"CytRx Corporation\">CYTR</a> <font color=\"green\">+14.2%</font>) is up on double normal volume in response to its announcement that it has reached the target number of progression events in its Phase 3 clinical trial assessing aldoxorubicin for the second-line treatment of soft tissue sarcomas (STS). Per the statistical analysis plan in the protocol, 191 events were required to trigger the analysis of the primary endpoint of progression-free survival. A contracted radiology group reviewed and verified the events and will analyze the scans.</li>\n<li>If all goes well, the company intends to initiate its rolling New Drug Application (NDA) by year end. Barring unforeseen delays, market launch for the indication should commence sometime in H2 2017.</li>\n<li>\n<a href=\"http://www.cytrx.com/oncology_programs\" target=\"_blank\">Aldoxorubicin </a>is a conjugate of the chemo agent doxorubicin and an acid-sensitive linker. The formulation improves efficacy and reduces toxicity.</li>\n<li>STS, a cancer that occurs in the soft tissues of the body (e.g., muscle, fat, blood vessels), strikes more than 40K Americans and Europeans each year resulting in 13K deaths.</li>\n<li>Now read <a href=\"https://seekingalpha.com/article/2831256-whats-to-like-about-cytrxs-brain-cancer-data\" target=\"_blank\">What's To Like About CytRx's Brain Cancer Data?</a>\n</li>\n<li>\n<strong>Update</strong>: In a regulatory filing, the company <a href=\"https://www.sec.gov/Archives/edgar/data/799698/000079969816000037/form8k_06072016.htm\" target=\"_blank\">announced </a>that top-line data on the PFS endpoint will be reported next month (July).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171319\" data-linked=\"CytRx hits target number of progression events in late-stage aldoxorubicin study in soft tissue cancer; shares up 14%\" data-tweet=\"$CYTR - CytRx hits target number of progression events in late-stage aldoxorubicin study in soft tissue cancer; shares up 14% https://seekingalpha.com/news/3171319-cytrx-hits-target-number-of-progression-events-in-late-stage-aldoxorubicin-study-in-soft?source=tweet\" data-url=\"https://seekingalpha.com/news/3171319-cytrx-hits-target-number-of-progression-events-in-late-stage-aldoxorubicin-study-in-soft\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171330\" data-ts=\"1459796300\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RTK\" target=\"_blank\">RTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171330-rentechplus-43-in-two-days-after-liquidity-improvements-revealed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rentech +43% in two days after liquidity improvements revealed</a></h4><ul>     <li>Rentech (<a href=\"https://seekingalpha.com/symbol/RTK\" title=\"Rentech, Inc\">RTK</a> <font color=\"green\">+4.2%</font>) extends Friday's gains that followed news that it closed the merger of Rentech Nitrogen Partners (NYSE:<a href=\"https://seekingalpha.com/symbol/RNF\" title=\"Rentech Nitrogen Partners, L.P.\">RNF</a>) and CVR Partners, which has enabled it to retire $142M of senior obligations to GSO Capital Partners; shares are up 43% since the announcement.</li>     <li>RTK says the acquisition improves its liquidity positioning, reduces future interest expenses and better positions itself to maximize the value of its investments within the wood fibre processing industry.</li>     <li>RTK also says it retained $109.8M of the total pre-tax proceeds from the deal and estimates it will pay $5M-$15M in taxes.</li>\n<li>Now read <a href=\"https://seekingalpha.com/news/3167557-rentech-revises-agreements-gso-assist-rnf-cvr-merger-closure\" target=\"_blank\"><strong>Rentech revises agreements with GSO to assist RNF-CVR merger closure</strong></a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171330\" data-linked=\"Rentech +43% in two days after liquidity improvements revealed\" data-tweet=\"$RTK $RTK $RNF - Rentech +43% in two days after liquidity improvements revealed https://seekingalpha.com/news/3171330-rentechplus-43-in-two-days-after-liquidity-improvements-revealed?source=tweet\" data-url=\"https://seekingalpha.com/news/3171330-rentechplus-43-in-two-days-after-liquidity-improvements-revealed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171328\" data-ts=\"1459795740\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NE\" target=\"_blank\">NE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171328-latent-optimism-noble-corp-jefferies-observes-in-hiking-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">&quot;Latent optimism&quot; at Noble Corp., Jefferies observes in hiking price target</a></h4><ul>     <li>Noble Corp. (<a href=\"https://seekingalpha.com/symbol/NE\" title=\"Noble Corporation plc\">NE</a> <font color=\"red\">-3%</font>) is lower despite a bullish note from Jefferies, which raises its price target for the shares to $9 from $7 as the company showed \"<a href=\"http://blogs.barrons.com/stockstowatchtoday/2016/04/04/noble-wait-one-analyst-is-sensing-latent-optimism-from-the-offshore-driller/\" target=\"_blank\">latent optimism</a>\" about a potential recovery during a meeting with management.</li>     <li>NE senses relative optimism from operators that crude oil should stabilize above $45/bbl, which could drive modest incremental rig demand, Jefferies says, noting that management sees very little new work in 2016 and thus the rig count likely will continue to fall through year-end 2016 but should stabilize in 2017, pending the oil price outlook.</li>     <li>Jefferies nevertheless maintain its Hold rating, and cautions that color on three market-indexed contracts and a dividend reduction in the next month could be near-term headwinds.</li>\n<li>Now read <a href=\"https://seekingalpha.com/news/3167540-noble-corp-downgraded-susquehanna-following-recent-rally\" target=\"_blank\"><strong>Noble Corp. downgraded at Susquehanna following recent rally</strong></a>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171328\" data-linked=\"&quot;Latent optimism&quot; at Noble Corp., Jefferies observes in hiking price target\" data-tweet=\"$NE - &quot;Latent optimism&quot; at Noble Corp., Jefferies observes in hiking price target https://seekingalpha.com/news/3171328-latent-optimism-noble-corp-jefferies-observes-in-hiking-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3171328-latent-optimism-noble-corp-jefferies-observes-in-hiking-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171323\" data-ts=\"1459793964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAL\" target=\"_blank\">HAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171323-doj-sues-valueact-over-disclosure-of-stakes-in-halliburton-baker-hughes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DoJ sues ValueAct over disclosure of stakes in Halliburton, Baker Hughes</a></h4><ul>     <li>The Justice Department <a href=\"https://www.justice.gov/opa/pr/justice-department-sues-valueact-violating-premerger-notification-requirements\" target=\"_blank\">files a civil suit</a> against the ValueAct Capital Management hedge fund for failing to tell the U.S. government about more than $2.5B in stock purchases in Halliburton (<a href=\"https://seekingalpha.com/symbol/HAL\" title=\"Halliburton Company\">HAL</a> <font color=\"red\">-3%</font>) and Baker Hughes (BHI <font color=\"red\">-5.5%</font>) after the oil companies announced their $35B planned merger in 2014.</li>     <li>The DoJ says ValueAct's purchase was a pre-merger notification violation of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the intent to influence the companies business decisions.</li>     <li>The violation \u201callowed ValueAct to become one of the largest shareholders of both Halliburton and Baker Hughes, without providing the government its statutory right to notice and prior review of the stock  purchases,\u201d the DoJ says.</li>     <li>Now read <a href=\"https://seekingalpha.com/news/3171228-ny-post-doj-leaning-halliburton-baker-hughes-deal\" target=\"_blank\"><strong>NY Post: DoJ leaning against Halliburton-Baker Hughes deal</strong></a>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171323\" data-linked=\"DoJ sues ValueAct over disclosure of stakes in Halliburton, Baker Hughes\" data-tweet=\"$HAL $HAL $BKR - DoJ sues ValueAct over disclosure of stakes in Halliburton, Baker Hughes https://seekingalpha.com/news/3171323-doj-sues-valueact-over-disclosure-of-stakes-in-halliburton-baker-hughes?source=tweet\" data-url=\"https://seekingalpha.com/news/3171323-doj-sues-valueact-over-disclosure-of-stakes-in-halliburton-baker-hughes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171317\" data-ts=\"1459791565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANIP\" target=\"_blank\">ANIP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171317-ani-pharma-ups-guidance-shares-rise-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ANI Pharma ups guidance; shares rise 12%</a></h4><ul>\n<li>Thinly traded micro cap ANI Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/ANIP\" title=\"ANI Pharmaceuticals, Inc.\">ANIP</a> <font color=\"green\">+12%</font>) is up on more than double normal volume, albeit on turnover of only 570K shares, in response to an increase in its 2016 guidance. The company now expects net revenues of $119M - 134M (up from $105M - 120M), non-GAAP EBITDA of $55M - 63M (up from $45M - 53M) and non-GAAP EPS of $3.54 - 3.91 (up from $2.94 - 3.31).</li>\n<li>Now read <a href=\"https://seekingalpha.com/article/3960172-ani-pharmaceuticals-fantastic-growth-offset-large-tail-risks\" target=\"_blank\">ANI Pharmaceuticals: Fantastic Growth Offset By Large Tail Risks</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171317\" data-linked=\"ANI Pharma ups guidance; shares rise 12%\" data-tweet=\"$ANIP - ANI Pharma ups guidance; shares rise 12% https://seekingalpha.com/news/3171317-ani-pharma-ups-guidance-shares-rise-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3171317-ani-pharma-ups-guidance-shares-rise-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171312\" data-ts=\"1459790130\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHM\" target=\"_blank\">PHM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171312-pultegroup-slumps-after-ceo-sets-exit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PulteGroup slumps after CEO sets exit</a></h4><ul>\n<li>Grandson of company founder Bill Pulte and former chairman Jim Grosfeld \"recently demanded an immediate CEO change and a different direction,\" <a href=\"http://www.nationalmortgagenews.com/news/people/pultegroup-ceo-dugas-to-step-down-under-pressure-from-founder-1075076-1.html?site=default_on&amp;utm_medium=email&amp;ET=nationalmortgage:e6433191:753877a:&amp;utm_source=newsletter&amp;utm_campaign=origination%20news-apr%204%202016&amp;st=email\" target=\"_blank\">according to a statement</a> from PulteGroup (<a href=\"https://seekingalpha.com/symbol/PHM\" title=\"PulteGroup, Inc.\">PHM</a> <font color=\"red\">-7.8%</font>).</li>\n<li>It's surprising, says Bloomberg's Drew Reading, noting CEO Richard Dugas' strategy to boost profitability has been working, with net income and gross margins both nicely higher in Q4 than a year earlier.</li>\n<li>Now read: <a href=\"https://seekingalpha.com/article/3960721-5-best-real-estate-stocks-low-interest-rates\" target=\"_blank\">5 Best Real Estate Stocks For Low Interest Rates</a> (March 24)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171312\" data-linked=\"PulteGroup slumps after CEO sets exit\" data-tweet=\"$PHM - PulteGroup slumps after CEO sets exit https://seekingalpha.com/news/3171312-pultegroup-slumps-after-ceo-sets-exit?source=tweet\" data-url=\"https://seekingalpha.com/news/3171312-pultegroup-slumps-after-ceo-sets-exit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171306\" data-ts=\"1459788651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171306-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers/ Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VA' title='Virgin America'>VA</a> <font color='green'>+42%</font>. <a href='https://seekingalpha.com/symbol/RKUS' title='Ruckus Wireless'>RKUS</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/SKYS' title='Sky Solar Holdings'>SKYS</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/STXS' title='Stereotaxis, Inc.'>STXS</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/EW' title='Edwards Lifesciences Corp'>EW</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/AAMC' title='Altisource Asset Management Corp'>AAMC</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a> <font color='green'>+15%</font>. GALE&nbsp;<font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VCEL' title='Vericel Corporation'>VCEL</a> <font color='red'>-35%</font>. <a href='https://seekingalpha.com/symbol/GBSN-OLD' title='Great Basin Scientific, Inc.'>GBSN</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/STAF' title='Staffing 360 Solutions, Inc.'>STAF</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/BABY' title='Natus Medical Incorporated'>BABY</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/IRMD' title='iRadimed Corp.'>IRMD</a> <font color='red'>-17%</font>. SWHC <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/CDRB' title='Code Rebel Corp'>CDRB</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/BRCD' title='Brocade Communications Systems, Inc.'>BRCD</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ARCW' title='ARC Group Worldwide, Inc.'>ARCW</a> <font color='red'>-14%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171306\" data-linked=\"Midday Gainers/ Losers\" data-tweet=\"$VA $RKUS $SKYS - Midday Gainers/ Losers https://seekingalpha.com/news/3171306-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3171306-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171304\" data-ts=\"1459788595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTK\" target=\"_blank\">PRTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171304-paratek-pharma-completes-enrollment-in-late-stage-study-of-omadacycline-in-absssi-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paratek Pharma completes enrollment in late-stage study of omadacycline in ABSSSI; shares up 4%</a></h4><ul>\n<li>Thinly traded micro cap Paratek Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/PRTK\" title=\"Paratek Pharmaceuticals, Inc.\">PRTK</a> <font color=\"green\">+4.4%</font>) is up on average volume in early trading. Earlier today, it announced that patient enrollment has been completed in its Phase 3 clinical trial assessing lead product candidate omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Top-line data should be available by mid-year.</li>\n<li>Omadacycline, a <a href=\"https://en.wikipedia.org/wiki/Tetracycline\" target=\"_blank\">tetracycline</a> antibiotic known as an <a href=\"http://www.paratekpharm.com/pdf/Mechanism%20of%20Action%20of%20the%20Novel%20Aminomethylcycline%20Antibiotic%20Omadacycline.pdf\" target=\"_blank\">aminomethylcycline</a>, has broad spectrum activity against Gram-positive, Gram-negative and atypical bacteria.</li>\n<li>Now read<a href=\"https://seekingalpha.com/article/3720436-paratek-pharmaceuticals-totally-mispriced-antibiotic-company-strong-data-supporting-likely\" target=\"_blank\"> Paratek Pharmaceuticals: Totally Mispriced Antibiotic Company With Strong Data Supporting Likely Phase 3 Success</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171304\" data-linked=\"Paratek Pharma completes enrollment in late-stage study of omadacycline in ABSSSI; shares up 4%\" data-tweet=\"$PRTK - Paratek Pharma completes enrollment in late-stage study of omadacycline in ABSSSI; shares up 4% https://seekingalpha.com/news/3171304-paratek-pharma-completes-enrollment-in-late-stage-study-of-omadacycline-in-absssi-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3171304-paratek-pharma-completes-enrollment-in-late-stage-study-of-omadacycline-in-absssi-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171303\" data-ts=\"1459788056\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAM\" target=\"_blank\">BAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171303-brookfield-vehicles-lower-after-barrons-treatment-muddy-waters-joins-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brookfield vehicles lower after Barron&#39;s treatment, Muddy Waters joins in</a></h4><ul>\n<li>\n<a href=\"https://seekingalpha.com/news/3171100-barrons-takes-look-brookfields-fair-value-estimates\" target=\"_blank\">A weekend <em>Barron's</em> article</a> noted that the majority of Brookfield Asset Management's (<a href=\"https://seekingalpha.com/symbol/BAM\" title=\"Brookfield Asset Management Inc.\">BAM</a> <font color=\"red\">-4.7%</font>) earnings in recent years are the result of noncash markups of the \"fair value\" of its investments.</li>\n<li>Taking a look at two key properties of Brookfield Infrastructure Partners (<a href=\"https://seekingalpha.com/symbol/BIP\" title=\"Brookfield Infrastructure Partners L.P.\">BIP</a> <font color=\"red\">-3%</font>), <em>Barron's</em> raised questions about how Brookfield's valuations were so much higher than those of its JV partners.</li>\n<li>Brookfield calls their valuations \"conservative.\" <a href=\"https://twitter.com/muddywatersre/status/716297001642528768\" target=\"_blank\">Muddy Waters isn't</a> buying it.</li>\n<li>Now read: <a href=\"https://seekingalpha.com/article/3962940-2015-intrinsic-value-brookfield-asset-management\" target=\"_blank\">2015 Intrinsic Value For Brookfield Asset Management</a> (April 4)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171303\" data-linked=\"Brookfield vehicles lower after Barron&#39;s treatment, Muddy Waters joins in\" data-tweet=\"$BAM $BAM $BIP - Brookfield vehicles lower after Barron&#39;s treatment, Muddy Waters joins in https://seekingalpha.com/news/3171303-brookfield-vehicles-lower-after-barrons-treatment-muddy-waters-joins-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3171303-brookfield-vehicles-lower-after-barrons-treatment-muddy-waters-joins-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171297\" data-ts=\"1459787550\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCX\" target=\"_blank\">OCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171297-oncocytes-liquid-biopsy-lung-cancer-test-advances-shares-up-40\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OncoCyte&#39;s liquid biopsy lung cancer test advances; shares up 40%</a></h4><ul>\n<li>Thinly traded micro cap OncoCyte (<a href=\"https://seekingalpha.com/symbol/OCX\" title=\"OncoCyte Corporation\">OCX</a> <font color=\"green\">+39.8%</font>) is up on almost a 5x surge in volume, albeit on turnover of less than 100K shares, in response to its announcement of a successful 620-subject research study on its lung cancer diagnostic test that validates the transition of the assay platform from Illumina (<a href=\"https://seekingalpha.com/symbol/ILMN\" title=\"Illumina, Inc.\">ILMN</a> <font color=\"green\">+1.3%</font>) microarrays to a Nanostring (<a href=\"https://seekingalpha.com/symbol/NSTG\" title=\"NanoString Technologies\">NSTG</a> <font color=\"red\">-2.3%</font>) <a href=\"http://www.nanostring.com/applications/technology\" target=\"_blank\">nCounter </a>instrument, the platform OncoCyte intends to use for commercialization. The study, which replicates an earlier one, was conducted by biomedical research organization The Wistar Institute.</li>\n<li>The company will now independently validate the results with its own follow-up study. If successful, it will execute the necessary analytic work to support the test's commercialization. If all goes well, commercial launch could happen in H1 2017. When launched, it will be the first commercially available, non-invasive diagnostic for the early detection of lung cancer.</li>\n<li>The value proposition of liquid biopsy, performed on a peripheral blood sample, is lower cost, greater convenience and much more patient-friendly that traditional tissue biopsy.</li>\n<li>Related tickers: (<a href=\"https://seekingalpha.com/symbol/TROV\" title=\"TrovaGene, Inc.\">TROV</a> <font color=\"green\">+2.1%</font>)(<a href=\"https://seekingalpha.com/symbol/TBIO\" title=\"Translate Bio\">TBIO</a> <font color=\"green\">+5%</font>)(<a href=\"https://seekingalpha.com/symbol/SQNM\" title=\"Sequenom, Inc.\">SQNM</a>)(<a href=\"https://seekingalpha.com/symbol/CDNA\" title=\"CareDx\">CDNA</a> <font color=\"red\">-1.2%</font>)(<a href=\"https://seekingalpha.com/symbol/ILMN\" title=\"Illumina, Inc.\">ILMN</a> <font color=\"green\">+1.3%</font>)(<a href=\"https://seekingalpha.com/symbol/FMI\" title=\"Foundation Medicine, Inc.\">FMI</a> <font color=\"green\">+3%</font>)(<a href=\"https://seekingalpha.com/symbol/BIOC\" title=\"Biocept, Inc.\">BIOC</a> <font color=\"red\">-0.8%</font>)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171297\" data-linked=\"OncoCyte&#39;s liquid biopsy lung cancer test advances; shares up 40%\" data-tweet=\"$OCX $OCX $ILMN - OncoCyte&#39;s liquid biopsy lung cancer test advances; shares up 40% https://seekingalpha.com/news/3171297-oncocytes-liquid-biopsy-lung-cancer-test-advances-shares-up-40?source=tweet\" data-url=\"https://seekingalpha.com/news/3171297-oncocytes-liquid-biopsy-lung-cancer-test-advances-shares-up-40\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171300\" data-ts=\"1459787208\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171300-ge-cut-to-hold-from-buy-bernstein-after-shares-hit-eight-year-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE cut to Hold from Buy at Bernstein after shares hit eight-year high</a></h4><ul>     <li>General Electric (<a href=\"https://seekingalpha.com/symbol/GE\" title=\"General Electric\">GE</a> <font color=\"red\">-1.9%</font>) sinks after shares are <a href=\"http://blogs.barrons.com/stockstowatchtoday/2016/04/04/general-electric-all-the-risks-none-of-the-upside/\" target=\"_blank\">downgraded to Market Perform</a> from Outperform at Bernstein, which cites valuation concerns after the stock recently hit an eight-year high at $32.</li>\n<li>Bernstein sees risks of rising competition in several of GE's businesses, that  growth in its health care segment will be challenged by pricing pressure, and the success of its power and aviation businesses are priced in.</li>     <li>The firm says many sources of upside are now 'baked into' the current share price\" even as GE still has many of the same risks, ranging from Alstom integration and power demand to a longer duration oil and gas business down-cycle to a potential air pocket in aviation within the next few years.</li>     <li>Bernstein also downgrades Danaher (<a href=\"https://seekingalpha.com/symbol/DHR\" title=\"Danaher Corporation\">DHR</a> <font color=\"red\">-1.7%</font>) and IDEX (<a href=\"https://seekingalpha.com/symbol/IEX\" title=\"IDEX Corporation\">IEX</a> <font color=\"red\">-1.6%</font>) to Market Perform from Outperform on valuation.</li>\n<li>Now read <a href=\"https://seekingalpha.com/article/3962114-general-electric-major-buy-signal-just-flashed\" target=\"_blank\"><strong>General Electric: A major buy signal just flashed</strong></a>\n</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3171300\" data-linked=\"GE cut to Hold from Buy at Bernstein after shares hit eight-year high\" data-tweet=\"$GE $GE $DHR - GE cut to Hold from Buy at Bernstein after shares hit eight-year high https://seekingalpha.com/news/3171300-ge-cut-to-hold-from-buy-bernstein-after-shares-hit-eight-year-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3171300-ge-cut-to-hold-from-buy-bernstein-after-shares-hit-eight-year-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171292\" data-ts=\"1459785416\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFSI\" target=\"_blank\">AFSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171292-amtrust-slides-dismisses-auditor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AmTrust slides as it dismisses auditor</a></h4><ul><li>AmTrust Financial (<a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a> <font color='red'>-4.6%</font>) which in the past <a href=\"https://seekingalpha.com/news/1780433-amtrust-lower-after-getting-barrons-treatment-over-weekend\" target=\"_blank\">has had to deal with</a> accounting allegations, <a href=\"http://www.sec.gov/Archives/edgar/data/1365555/000136555516000250/form8k4116.htm\" target=\"_blank\">dismisses BDO</a> as its public accounting firm, and awards the work to KPMG.</li><li>Now read: <a href=\"https://seekingalpha.com/article/3937406-amtrust-investment-income-keep-workers-compensation-growth\" target=\"_blank\">AmTrust: Investment Income Can't Keep Up With Workers' Compensation Growth</a> (Feb. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3171292\" data-linked=\"AmTrust slides as it dismisses auditor\" data-tweet=\"$AFSI - AmTrust slides as it dismisses auditor https://seekingalpha.com/news/3171292-amtrust-slides-dismisses-auditor?source=tweet\" data-url=\"https://seekingalpha.com/news/3171292-amtrust-slides-dismisses-auditor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171288\" data-ts=\"1459784586\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRMD\" target=\"_blank\">IRMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171288-fda-rejects-iradimeds-marketing-app-for-iv-infusion-pump-shares-slump-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA rejects IRADIMED&#39;s marketing app for IV infusion pump; shares slump 15%</a></h4><ul>\n<li>Thinly traded micro cap IRADIMED (<a href=\"https://seekingalpha.com/symbol/IRMD\" title=\"iRadimed Corp.\">IRMD</a> <font color=\"red\">-15.3%</font>) is down on triple normal volume, albeit on turnover of only ~250K shares, in response to its announcement (after the close on Friday) that the FDA rejected its 510(k) application seeking clearance of its <a href=\"http://www.iradimed.com/en-us/products/mridium3860.php\" target=\"_blank\">MRidium 3860+ MRI compatible IV infusion pump</a> due to non-substantial equivalence.</li>\n<li>Specifically, the application did not contain sufficient human factors data demonstrating that its Dose Errors Reduction System (DERS) was adequately validated. Validation was undermined when two of the 56 test subjects in the human factors tests unintentionally bypassed the DERS feature and thereby avoided its hard dose limits that healthcare institutions can program into the devices.</li>\n<li>The company intends to appeal the decision.</li>\n<li>In September 2014, the FDA ordered the company to stop selling its MRI-compatible infusion pumps and submit a new 510(k) application. It complied but resumed shipping the product in December without the DERS feature with the agency's consent. A month later, it resumed shipping the systems with the DERS feature, also with the FDA's consent. Its rejection of the 510(k) could result in the withdrawal of the consent and the cessation of shipping DERS-enabled pumps.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171288\" data-linked=\"FDA rejects IRADIMED&#39;s marketing app for IV infusion pump; shares slump 15%\" data-tweet=\"$IRMD - FDA rejects IRADIMED&#39;s marketing app for IV infusion pump; shares slump 15% https://seekingalpha.com/news/3171288-fda-rejects-iradimeds-marketing-app-for-iv-infusion-pump-shares-slump-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3171288-fda-rejects-iradimeds-marketing-app-for-iv-infusion-pump-shares-slump-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171286\" data-ts=\"1459784245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/F\" target=\"_blank\">F</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171286-major-automaker-stocks-go-in-reverse-after-model-3-steps-out\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Major automaker stocks go in reverse after Model 3 steps out</a></h4><ul> <li>Ford (<a href=\"https://seekingalpha.com/symbol/F\" title=\"Ford Motor Company\">F</a> <font color=\"red\">-2.2%</font>), General Motors (<a href=\"https://seekingalpha.com/symbol/GM\" title=\"General Motors Company\">GM</a> <font color=\"red\">-1.9%</font>), and Toyota (<a href=\"https://seekingalpha.com/symbol/TM\" title=\"Toyota Motor Corporation\">TM</a> <font color=\"red\">-2.4%</font>) are all down for a second straight day after overall U.S. sales came in below expectations for March.</li> <li>There's also a bit of a Tesla overhang over the major automakers as the weekend's <a href=\"https://seekingalpha.com/news/3171144-tesla-model-3-now-276k-pre-orders\" target=\"_blank\">strong tally</a> of Model 3 pre-orders is the one of the first concrete indications that the EV automaker could be a market share disrupter. If even half of Tesla's early round of orders comes to fruition, about $5B in consumer spending on automobiles is going in a different direction than Detroit or Tokyo. Naturally, Tesla enthusiasts think the number will be much higher.</li>\n<li>Daimler (<a href=\"https://seekingalpha.com/symbol/DDAIF\" title=\"Daimler AG\">OTCPK:DDAIF</a> <font color=\"red\">-1.4%</font>) and BMW (BAMXY <font color=\"red\">-1.4%</font>) are also weak on the day amid the OEM gloom.</li> <li>Now read <a href=\"https://seekingalpha.com/article/3962809-b-tesla-b-model-3-existential-crisis-auto-industry\" target=\"_blank\"><strong>Tesla Model 3: Existential Crisis For The Auto Industry</strong></a><strong> </strong>\n</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3171286\" data-linked=\"Major automaker stocks go in reverse after Model 3 steps out\" data-tweet=\"$F $F $GM - Major automaker stocks go in reverse after Model 3 steps out https://seekingalpha.com/news/3171286-major-automaker-stocks-go-in-reverse-after-model-3-steps-out?source=tweet\" data-url=\"https://seekingalpha.com/news/3171286-major-automaker-stocks-go-in-reverse-after-model-3-steps-out\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>68&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171282\" data-ts=\"1459783179\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBSN\" target=\"_blank\">GBSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171282-great-basin-completes-warrant-exchange-shares-down-26\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Great Basin completes warrant exchange; shares down 26%</a></h4><ul>\n<li>Great Basin Scientific (<a href=\"https://seekingalpha.com/symbol/GBSN-OLD\" title=\"Great Basin Scientific, Inc.\">GBSN</a> <font color=\"red\">-26.3%</font>) is down on more than double normal volume in response to its announcement that it has completed the exchange of all Series E Warrants for 650,160 shares of common stock. According to the company, it reduced the dilution by 60% considering the total number of exercisable shares was 1.68M, which could have potentially increased to 3.36M shares at a future date under the anti-dilution provision.</li>\n<li>The Series E Warrants were issued in conjunction with the February 24, 2016 public financing and were not exercisable until February 2017.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171282\" data-linked=\"Great Basin completes warrant exchange; shares down 26%\" data-tweet=\"$GBSN $GBSN-OLD - Great Basin completes warrant exchange; shares down 26% https://seekingalpha.com/news/3171282-great-basin-completes-warrant-exchange-shares-down-26?source=tweet\" data-url=\"https://seekingalpha.com/news/3171282-great-basin-completes-warrant-exchange-shares-down-26\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171278\" data-ts=\"1459781931\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAKP\" target=\"_blank\">DAKP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171278-dakota-plains-cfo-brady-resigns-jim-thornton-to-serve-interim-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dakota Plains CFO Brady resigns; Jim Thornton to serve as interim CFO</a></h4><ul>     <li>Dakota Plains (<a href=\"https://seekingalpha.com/symbol/DAKP\" title=\"Dakota Plains Holdings, Inc.\">OTC:DAKP</a> <font color=\"green\">+3.9%</font>) says CFO Timothy Brady has resigned, and executive VP for strategy and general counsel Jim Thornton will assume the responsibilities as interim CFO.</li>     <li>Thornton has served as general counsel and secretary since joining the company in 2013 and as executive VP for strategy since last December.</li>     <li>Brady joined DAKP as CFO in 2012, and was instrumental in taking the company public; he had been a founder and CFO of Encore Energy.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171278\" data-linked=\"Dakota Plains CFO Brady resigns; Jim Thornton to serve as interim CFO\" data-tweet=\"$DAKP - Dakota Plains CFO Brady resigns; Jim Thornton to serve as interim CFO https://seekingalpha.com/news/3171278-dakota-plains-cfo-brady-resigns-jim-thornton-to-serve-interim-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3171278-dakota-plains-cfo-brady-resigns-jim-thornton-to-serve-interim-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171274\" data-ts=\"1459781389\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ET\" target=\"_blank\">ET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171274-energy-transfer-partners-cut-to-hold-stifel-citing-looming-challenges\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy Transfer Partners cut to Hold at Stifel, citing &quot;looming challenges&quot;</a></h4><ul>     <li>Energy Transfer Partners (ETP <font color=\"red\">-2.6%</font>) is <a href=\"http://blogs.barrons.com/incomeinvesting/2016/04/04/citing-challenges-ahead-stifel-downgrades-energy-transfer\" target=\"_blank\">downgraded to Hold</a> from Buy at Stifel, which says ETP's valuation seems high given the looming challenges associated with the <a href=\"https://seekingalpha.com/news/search?query=energy+transfer+williams\" target=\"_blank\">merger</a> of Energy Transfer Equity (ETE <font color=\"red\">-2%</font>) and Williams (<a href=\"https://seekingalpha.com/symbol/WMB\" title=\"Williams Companies Inc\">WMB</a>, <a href=\"https://seekingalpha.com/symbol/WPZ\" title=\"Williams Partners L.P.\">WPZ</a>).</li>     <li>Stifel also continues to assume ETP will require $500M of equity capital to complete its 2016 budget, which it believes is another reason to be cautious.</li>     <li>Current multiples do not appear excessive, given  ETP's diversified largely fee-based assets, but the firm expects near-term challenges that may limit further expansion.</li>     <li>Stifel also believes ETP's distribution is secure and the 13.4% yield is attractive, but near-term challenges may limit price appreciation.</li>     <li>Now read <a href=\"https://seekingalpha.com/article/3959167-energy-transfer-partners-can-sail-storm-without-cutting-dividends\" target=\"_blank\"><strong>Energy Transfer Partners can sail through this storm without cutting dividends</strong></a>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171274\" data-linked=\"Energy Transfer Partners cut to Hold at Stifel, citing &quot;looming challenges&quot;\" data-tweet=\"$ET $ET $WMB - Energy Transfer Partners cut to Hold at Stifel, citing &quot;looming challenges&quot; https://seekingalpha.com/news/3171274-energy-transfer-partners-cut-to-hold-stifel-citing-looming-challenges?source=tweet\" data-url=\"https://seekingalpha.com/news/3171274-energy-transfer-partners-cut-to-hold-stifel-citing-looming-challenges\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171272\" data-ts=\"1459781230\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171272-lululemon-stretching-to-52-week-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon stretching to 52-week high</a></h4><ul> <li>Shares of Lululemon (<a href=\"https://seekingalpha.com/symbol/LULU\" title=\"Lululemon Athletica Inc.\">LULU</a> <font color=\"green\">+1%</font>) are very close to trading in the $70s for the first time in almost year as post-earnings sentiment remains favorable.</li> <li>Earieir today. Morgan Stanely <a href=\"http://www.marketbeat.com/stocks/NASDAQ/LULU/\" target=\"_blank\">backed</a> its Overweight rating in a fresh note to investors, while JPMorgan raised its prIce target up to $75. The Strett-high PT is $80 from Oppenheimer.</li> <li>Now read <a href=\"https://seekingalpha.com/article/3962341-lululemon-athletica-strong-mission-can-overcome-adversity\" target=\"_blank\"><strong>Lululemon Athletica: A Strong Mission Can Overcome Adversity</strong></a>\n</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3171272\" data-linked=\"Lululemon stretching to 52-week high\" data-tweet=\"$LULU - Lululemon stretching to 52-week high https://seekingalpha.com/news/3171272-lululemon-stretching-to-52-week-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3171272-lululemon-stretching-to-52-week-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171263\" data-ts=\"1459779645\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WWE\" target=\"_blank\">WWE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171263-wweplus-3-wrestlemania-breaks-attendance-gross-revenue-records\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WWE +3% as WrestleMania breaks attendance, gross revenue records</a></h4><ul>   <li>Is it the golden age for wrestling again? WrestleMania 32 became the highest-grossing live event for World Wrestling Entertainment (<a href=\"https://seekingalpha.com/symbol/WWE\" title=\"World Wrestling Entertainment, Inc.\">WWE</a> <font color=\"green\">+3%</font>) and set an attendance record last night, drawing 101,763 to surpass a mark of 93,173 set in 1987 with WrestleMania 3.</li>    <li>A near five-hour show that had been criticized in the lead-up for featuring storylines from part-time (and older) wrestlers put a couple of surprises in, including a match that featured popular legacy wrestler Dwayne \"The Rock\" Johnson and a returning John Cena.</li>    <li>The event, in Arlington, Texas, became the highest-grossing live event ever for WWE, drawing $17.3M and easily surpassing last year's previous record of $12.6M.</li>    <li>A rash of injuries had weakened the annual event's card this year.</li>    <li>Heading into the weekend event, Macquarie reiterated its hold rating on the stock and price target of $18, while Pacific Crest had launched coverage at Overweight with a $22 (which holds 23% upside from today's raised price).</li>    <li>Now read <a href=\"https://seekingalpha.com/article/3957064-demystifying-wwes-business\" target=\"_blank\"><b>Demystifying WWE's Business »</b></a>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171263\" data-linked=\"WWE +3% as WrestleMania breaks attendance, gross revenue records\" data-tweet=\"$WWE - WWE +3% as WrestleMania breaks attendance, gross revenue records https://seekingalpha.com/news/3171263-wweplus-3-wrestlemania-breaks-attendance-gross-revenue-records?source=tweet\" data-url=\"https://seekingalpha.com/news/3171263-wweplus-3-wrestlemania-breaks-attendance-gross-revenue-records\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171255\" data-ts=\"1459778186\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SALM\" target=\"_blank\">SALM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171255-salem-media-acquires-carlsons-retirement-watch-properties\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Salem Media acquires Carlson&#39;s Retirement Watch properties</a></h4><ul>   <li>Salem Media Group (<a href=\"https://seekingalpha.com/symbol/SALM\" title=\"Salem Media Group, Inc\">SALM</a> <font color=\"green\">+1.8%</font>) has made another investing-related acquisition, taking on Bob Carlson's Retirement Watch newsletter and its site, RetirementWatch.com.</li>    <li>The Christian/conservative media firm has been adding assets to its Eagle Financial Publications unit. In November it <a href=\"https://seekingalpha.com/news/2882196-salem-media-group-acquires-dividendyieldhunter-com\" target=\"_blank\">added DividendYieldHunter.com</a> to digital operations including EagleDailyInvestor.com and ETFU.com.</li>    <li>Retirement Watch is targeted at all aspects of retirement planning: investments, Social Security, IRAs, pension plans, annuities, estate planning, medical coverage, income taxes and more.</li>    <li>Now read <a href=\"https://seekingalpha.com/article/3421516-donald-trumps-grabbing-of-attention-here-is-a-stock-poised-to-gain-from-it\" target=\"_blank\"><b>Donald Trump's Grabbing Of Attention: Here Is A Stock Poised To Gain From It »</b></a>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171255\" data-linked=\"Salem Media acquires Carlson&#39;s Retirement Watch properties\" data-tweet=\"$SALM - Salem Media acquires Carlson&#39;s Retirement Watch properties https://seekingalpha.com/news/3171255-salem-media-acquires-carlsons-retirement-watch-properties?source=tweet\" data-url=\"https://seekingalpha.com/news/3171255-salem-media-acquires-carlsons-retirement-watch-properties\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171239\" data-ts=\"1459775632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171239-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/VA\" title=\"Virgin America\">VA</a> <font color=\"green\">+40%</font>. <a href=\"https://seekingalpha.com/symbol/RKUS\" title=\"Ruckus Wireless\">RKUS</a> <font color=\"green\">+32%</font>. <a href=\"https://seekingalpha.com/symbol/ZFGN\" title=\"Zafgen, Inc.\">ZFGN</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/EW\" title=\"Edwards Lifesciences Corp\">EW</a> <font color=\"green\">+12%</font>. <a href=\"https://seekingalpha.com/symbol/TRXC\" title=\"TransEnterix, Inc.\">TRXC</a> <font color=\"green\">+11%</font>. <a href=\"https://seekingalpha.com/symbol/EDAP\" title=\"EDAP TMS S.A.\">EDAP</a> <font color=\"green\">+11%</font>. <a href=\"https://seekingalpha.com/symbol/XBIT\" title=\"Xbiotech\">XBIT</a> <font color=\"green\">+9%</font>. <a href=\"https://seekingalpha.com/symbol/GRPN\" title=\"Groupon, Inc.\">GRPN</a> <font color=\"green\">+7%</font>. <a href=\"https://seekingalpha.com/symbol/SKYS\" title=\"Sky Solar Holdings\">SKYS</a> <font color=\"green\">+6%</font>. <a href=\"https://seekingalpha.com/symbol/GNCA\" title=\"Genocea Biosciences, Inc.\">GNCA</a> <font color=\"green\">+5%</font>.</li> <li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/AWI\" title=\"Armstrong World Industries, Inc.\">AWI</a> <font color=\"red\">-13%</font>. <a href=\"https://seekingalpha.com/symbol/BRCD\" title=\"Brocade Communications Systems, Inc.\">BRCD</a> <font color=\"red\">-13%</font>. <a href=\"https://seekingalpha.com/symbol/PGNX\" title=\"Progenics Pharmaceuticals Inc.\">PGNX</a> <font color=\"red\">-7%</font>. <a href=\"https://seekingalpha.com/symbol/JMEI\" title=\"Jumei International Holding Limited\">JMEI</a> <font color=\"red\">-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3171239\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$VA $RKUS $ZFGN - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3171239-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3171239-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171238\" data-ts=\"1459775614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AOBC\" target=\"_blank\">AOBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171238-smith-wesson-clipped-valuation-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Smith &amp; Wesson clipped by valuation concerns</a></h4><ul>     <li>Smith &amp; Wesson (SWHC) slides in early trading after both Cowen and BB&amp;T <a href=\"http://www.marketbeat.com/stocks/NASDAQ/SWHC/\" target=\"_blank\">lower</a> their rating on the stock due to valuation.</li>     <li>Cowen shifts to Market Perform from Outperform, while BB&amp;T is down to Neutral from Buy.</li>\n<li>Some Seeking Alpha contributors are of the opinion that the extended Smith &amp; Wesson isn't over yet.</li>             <li>Now read <a href=\"https://seekingalpha.com/article/3960306-gun-stocks-still-buy-2016-onward\" target=\"_blank\"><strong>Why Gun Stocks Are Still A Buy Through 2016 And Onward</strong></a> and/or <a href=\"https://seekingalpha.com/article/3961074-smith-and-wesson-firing-future-growth-returns\" target=\"_blank\"><strong>Smith &amp; Wesson: Firing Up Future Growth And Returns</strong></a><strong> </strong>\n</li>\n<li>SWHC <font color=\"red\">-5.44%</font> premarket to $26.25.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171238\" data-linked=\"Smith &amp; Wesson clipped by valuation concerns\" data-tweet=\"$AOBC - Smith &amp; Wesson clipped by valuation concerns https://seekingalpha.com/news/3171238-smith-wesson-clipped-valuation-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3171238-smith-wesson-clipped-valuation-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171235\" data-ts=\"1459775120\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BABY\" target=\"_blank\">BABY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171235-natus-medical-sees-q1-revenue-of-87_5m-below-guidance-shares-off-12-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natus Medical sees Q1 revenue of $87.5M, below guidance; shares off 12% premarket</a></h4><ul>\n<li>Natus Medical (NASDAQ:<a href=\"https://seekingalpha.com/symbol/BABY\" title=\"Natus Medical Incorporated\">BABY</a>) is down <font color=\"red\">12%</font> premarket on light volume in response to its announcement of preliminary Q1 revenues of $87.5M, below previous guidance of $91.5M - 92.5M, excluding revenue from the Venezuela Ministry of Health contract (the company received no revenue from the contract in Q1).</li>\n<li>The Q1 earnings call will start at 11:00 am ET on Wednesday, April 20.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171235\" data-linked=\"Natus Medical sees Q1 revenue of $87.5M, below guidance; shares off 12% premarket\" data-tweet=\"$BABY $NTUS - Natus Medical sees Q1 revenue of $87.5M, below guidance; shares off 12% premarket https://seekingalpha.com/news/3171235-natus-medical-sees-q1-revenue-of-87_5m-below-guidance-shares-off-12-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3171235-natus-medical-sees-q1-revenue-of-87_5m-below-guidance-shares-off-12-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171228\" data-ts=\"1459774392\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHGE\" target=\"_blank\">BHGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171228-ny-post-doj-leaning-against-halliburton-baker-hughes-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NY Post: DoJ leaning against Halliburton-Baker Hughes deal</a></h4><ul>     <li>Baker Hughes (BHI) <font color=\"red\">-2.2%</font> premarket following a <em>NY Post</em> report that Halliburton (NYSE:<a href=\"https://seekingalpha.com/symbol/HAL\" title=\"Halliburton Company\">HAL</a>) is making a last-ditch bid to save their proposed merger but the Justice Department is <a href=\"http://nypost.com/2016/04/03/halliburton-throws-hail-mary-to-save-35b-deal-with-baker-hughes/\" target=\"_blank\">leaning against it</a>.</li>     <li>The DoJ has not made a final decision on whether to file a lawsuit to block the deal, but it could announce its opposition as soon as this week's American Bar Association annual antitrust conference  in Washington, according to the report.</li>\n<li>HAL is on the hook to pay a $3.5B break-up fee to BHI if the deal falls apart; BHI also could walk away from the deal at the end of April - and might  do so - to collect the fee if the DoJ does not act by  that time, the report says.</li>\n<li>Regulators reportedly have asked HAL to sell assets with ~$10B in revenue, which it is struggling to do after the collapse in  oil prices; <a href=\"https://seekingalpha.com/symbol/GE\" title=\"General Electric\">GE</a> is said to be the only company willing to buy some of the assets, with Weatherford (NYSE:<a href=\"https://seekingalpha.com/symbol/WFT\" title=\"Weatherford International Ltd.\">WFT</a>) out of the bidding.</li>     <li>Now read <a href=\"https://seekingalpha.com/article/3961258-halliburton-baker-hughes-time-cut-losses\" target=\"_blank\"><strong>Halliburton and Baker Hughes: Is it time to cut losses?</strong></a>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"3171228\" data-linked=\"NY Post: DoJ leaning against Halliburton-Baker Hughes deal\" data-tweet=\"$BHGE $BKR $HAL - NY Post: DoJ leaning against Halliburton-Baker Hughes deal https://seekingalpha.com/news/3171228-ny-post-doj-leaning-against-halliburton-baker-hughes-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3171228-ny-post-doj-leaning-against-halliburton-baker-hughes-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3171227\" data-ts=\"1459773779\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3171227-smith-wesson-gets-knocked-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Smith &amp; Wesson gets knocked with downgrades</a></h4><ul>\n<li>BB&amp;T cut its rating on the gun maker to Hold from Buy, on a valuation basis and due to a slowdown in insider buying.</li>\n<li>Cowen downgrades shares from Outperform to a Market Perform, citing slowing March NICS data and share performance year-to-date.</li>\n<li>The stock was also lowered to Neutral from Buy at CL King.</li>\n<li>SWHC <font color=\"red\">-6.5%</font> premarket</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3171227\" data-linked=\"Smith &amp; Wesson gets knocked with downgrades\" data-tweet=\"Smith &amp; Wesson gets knocked with downgrades https://seekingalpha.com/news/3171227-smith-wesson-gets-knocked-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3171227-smith-wesson-gets-knocked-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":35,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}